Category: BioAI

  • Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety

    German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process. Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine […]